Blueprint Medicines to Report Fourth Quarter and Full Year 2018 Financial Results on Tuesday, February 26, 2019
To access the live conference call, please dial (855) 728-4793 (domestic) or (503) 343-6666 (international), and refer to conference ID 26735762. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of
Blueprint Medicines is a precision therapy company striving to improve human health. With a focus on genomically defined cancers, rare diseases and cancer immunotherapy, we are developing transformational medicines rooted in our leading expertise in protein kinases, which are proven drivers of disease. Our uniquely targeted, scalable approach empowers the rapid design and development of new treatments and increases the likelihood of clinical success. We are currently advancing four investigational medicines in clinical development, along with multiple research programs. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2018-financial-results-on-tuesday-february-26-2019-300796794.html
Media and Investor Relations Contacts, Jim Baker, Vice President, Corporate Affairs, Blueprint Medicines, 617-844-8236, JBaker@blueprintmedicines.com; Hannah Deresiewicz, Stern Investor Relations, Inc., 212-362-1200, firstname.lastname@example.org